P. Urbas
Impact in
- Biotechnology top 1%
- Microbial Inactivation Methods
- Transgenic Plants and Applications
- Immunology top 10%
- Immunotherapy and Immune Responses
- Toxin Mechanisms and Immunotoxins
Papers in
- Oncology 8
- Cancer Treatment and Pharmacology 3
- HER2/EGFR in Cancer Research 3
- CAR-T cell therapy research 3
-
- Melanoma and MAPK Pathways 3
- Co-authors
- Ronald C. DeConti (9 shared papers)Adil Daud (11 shared papers)Stephanie Andrews (9 shared papers)Vernon K. Sondak (8 shared papers)Adam I. Riker (3 shared papers)Pamela N. Münster (3 shared papers)Daniel M. Sullivan (2 shared papers)Jane L. Messina (3 shared papers)
- Journals
- Journal of Clinical Oncology (6 papers)British Journal of Cancer (2 papers)Cancer Chemotherapy and Pharmacology (1 paper)Clinical Cancer Research (1 paper)Journal of Immunotherapy (1 paper)
- Partner nations
- United StatesGermany
In The Last Decade
P. Urbas
12 papers receiving 796 citations
P. Urbas's Hit Papers
Peers
Comparison fields: 5 of 62
- Biotechnology 386
- Immunology 308
- Oncology 267
- Biomedical Engineering 225
- Physiology 22
Countries citing papers authored by P. Urbas
This map shows the geographic impact of P. Urbas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Urbas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Urbas more than expected).
Fields of papers citing papers by P. Urbas
This network shows the impact of papers produced by P. Urbas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Urbas. The network helps show where P. Urbas may publish in the future.
Co-authors
The 25 scholars most cited alongside P. Urbas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma Hit paper breakdown → | 2008 | 503 |
| 2 | 2008 | 135 | |
| 3 | 2005 | 57 | |
| 4 | 2011 | 33 | |
| 5 | 2010 | 31 | |
| 6 | 2010 | 17 | |
| 7 | 2010 | 12 | |
| 8 | 2008 | 8 | |
| 9 | 2009 | 8 | |
| 10 | 2009 | 6 | |
| 11 | 2006 | 2 | |
| 12 | 2010 | 2 |
About P. Urbas
P. Urbas is a scholar working on Oncology, Molecular Biology, Hematology, Immunology and Infectious Diseases, having authored 12 papers that have together received 814 indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (4 papers), Multiple Myeloma Research and Treatments (4 papers), Cancer Treatment and Pharmacology (3 papers), Melanoma and MAPK Pathways (3 papers), HER2/EGFR in Cancer Research (3 papers), CAR-T cell therapy research (3 papers), Antifungal resistance and susceptibility (2 papers) and Microbial Inactivation Methods (2 papers). The work is most often cited by research in Biotechnology (386 citations), Immunology (308 citations), Oncology (267 citations), Biomedical Engineering (225 citations) and Physiology (22 citations). P. Urbas has collaborated with scholars based in United States and Germany. Frequent co-authors include Ronald C. DeConti, Adil Daud, Stephanie Andrews, Vernon K. Sondak, Adam I. Riker, Pamela N. Münster, Daniel M. Sullivan, Jane L. Messina, Kenneth E. Ugen and Richard Heller. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, Cancer Chemotherapy and Pharmacology, Clinical Cancer Research and Journal of Immunotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.